Personalis Inc
PSNL6.930USD
-0.255-3.55%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
615.01MMarket Cap
LossP/E TTM
More Details of Personalis Inc Company
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.
Personalis Inc Info
Ticker SymbolPSNL
Company namePersonalis Inc
IPO dateJun 20, 2019
CEOMr. Christopher M. (Chris) Hall
Number of employees229
Security typeOrdinary Share
Fiscal year-endJun 20
Address6600 Dumbarton Circle
CityFREMONT
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94555
Phone16507521300
Websitehttps://www.personalis.com/
Ticker SymbolPSNL
IPO dateJun 20, 2019
CEOMr. Christopher M. (Chris) Hall
Company Executives of Personalis Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Aaron Tachibana
Mr. Aaron Tachibana
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
163.21K
-0.39%
Dr. Richard Chen, M.D.
Dr. Richard Chen, M.D.
Executive Vice President - Research and Development, Chief Medical Officer
Executive Vice President - Research and Development, Chief Medical Officer
120.75K
-0.37%
Ms. Lonnie Shoff
Ms. Lonnie Shoff
Independent Director
Independent Director
20.63K
+99.99%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Chairman of the Board
Independent Chairman of the Board
13.51K
--
Mr. Stephen Moore
Mr. Stephen Moore
Senior Vice President, Chief Legal Officer, and Corporate Secretary
Senior Vice President, Chief Legal Officer, and Corporate Secretary
--
--
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Independent Director
Independent Director
--
--
Ms. Olivia K. Bloom, CPA
Ms. Olivia K. Bloom, CPA
Independent Director
Independent Director
--
--
Mr. A. Blaine Bowman
Mr. A. Blaine Bowman
Independent Director
Independent Director
--
--
Mr. Christopher M. (Chris) Hall
Mr. Christopher M. (Chris) Hall
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Aaron Tachibana
Mr. Aaron Tachibana
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
163.21K
-0.39%
Dr. Richard Chen, M.D.
Dr. Richard Chen, M.D.
Executive Vice President - Research and Development, Chief Medical Officer
Executive Vice President - Research and Development, Chief Medical Officer
120.75K
-0.37%
Ms. Lonnie Shoff
Ms. Lonnie Shoff
Independent Director
Independent Director
20.63K
+99.99%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Chairman of the Board
Independent Chairman of the Board
13.51K
--
Mr. Stephen Moore
Mr. Stephen Moore
Senior Vice President, Chief Legal Officer, and Corporate Secretary
Senior Vice President, Chief Legal Officer, and Corporate Secretary
--
--
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
16.34M
95.00%
Others
860.15K
5.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Sep 3
Updated: Wed, Sep 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Merck & Co Inc
15.82%
Tempus AI Inc
14.32%
Lightspeed Venture Partners
9.19%
ARK Investment Management LLC
8.00%
BlackRock Institutional Trust Company, N.A.
4.27%
Other
48.39%
Shareholders
Shareholders
Proportion
Merck & Co Inc
15.82%
Tempus AI Inc
14.32%
Lightspeed Venture Partners
9.19%
ARK Investment Management LLC
8.00%
BlackRock Institutional Trust Company, N.A.
4.27%
Other
48.39%
Shareholder Types
Shareholders
Proportion
Corporation
30.14%
Investment Advisor
22.29%
Investment Advisor/Hedge Fund
12.99%
Venture Capital
9.19%
Private Equity
3.24%
Hedge Fund
2.70%
Research Firm
1.55%
Individual Investor
1.14%
Pension Fund
0.60%
Other
16.17%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
235
47.23M
53.19%
-84.21K
2025Q2
227
69.99M
79.03%
+1.80M
2025Q1
223
76.78M
86.93%
+10.49M
2024Q4
213
73.54M
83.34%
+21.51M
2024Q3
203
51.51M
73.15%
+1.63M
2024Q2
208
30.80M
57.54%
-8.76M
2024Q1
264
31.11M
59.99%
-9.40M
2023Q4
271
31.05M
62.33%
-8.25M
2023Q3
297
34.10M
70.92%
-7.87M
2023Q2
312
35.53M
73.99%
-8.07M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Merck & Co Inc
14.04M
15.84%
--
--
Jun 30, 2025
Tempus AI Inc
12.72M
14.34%
--
--
Sep 11, 2025
Lightspeed Venture Partners
8.16M
9.2%
--
--
Jun 30, 2025
ARK Investment Management LLC
7.11M
8.02%
-80.27K
-1.12%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.80M
4.28%
+2.10M
+123.36%
Jun 30, 2025
The Vanguard Group, Inc.
3.14M
3.54%
+1.85M
+143.07%
Jun 30, 2025
AIGH Capital Management, LLC.
2.79M
3.14%
-194.57K
-6.53%
Jun 30, 2025
abrdn Inc.
1.76M
1.98%
+54.71K
+3.21%
Jun 30, 2025
Blue Water Life Science Advisors, LP.
1.68M
1.89%
+500.90K
+42.62%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.37M
1.54%
+851.42K
+165.59%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
ARK Genomic Revolution ETF
4.51%
Invesco NASDAQ Future Gen 200 ETF
0.65%
Global X Genomics & Biotechnology ETF
0.47%
ProShares Ultra Nasdaq Biotechnology
0.06%
iShares Micro-Cap ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
Avantis US Small Cap Equity ETF
0.04%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
ProShares UltraPro Russell2000
0.01%
View more
ARK Genomic Revolution ETF
Proportion4.51%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.65%
Global X Genomics & Biotechnology ETF
Proportion0.47%
ProShares Ultra Nasdaq Biotechnology
Proportion0.06%
iShares Micro-Cap ETF
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.06%
Avantis US Small Cap Equity ETF
Proportion0.04%
iShares Biotechnology ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
